Here, we report that the full-length form level of DYRK1A is decreased both in plasma and CSF of symptomatic DS groups (pDS and dDS) compared to the asymptomatic DS group (aDS), and in sporadic AD patients compared to controls. This evidence concerns the gene DYRK1A and Dravet syndrome.